Affiliated with uOttawa

REaCT
REthinking Clinical Trials

REaCT-Mg

REaCT-Mg

Magnesium replacement strategies for patients receiving palliative-intent treatment with Cisplatin, Carboplatin, Panitumumab or Cetuximab 

Principal Investigator(s): Dr. Michael Vickers

ClinicalTrials.gov: NCT02690012
Hypomagnesemia is a common consequence of many anti-cancer therapies. However optimal replacement strategies are unknown. The trial assessed the feasibility of comparing the benefits of treating hypomagnesemia to magnesium oxide or magnesium citrate in patients receiving palliative treatment with cisplatin, carboplatin, Panitumumab or Cetuximab. This study has been completed.

Sites: The Ottawa Hospital

Tags: Palliative chemotherapy

Publications:

  • A comparison of oral magnesium supplements for cancer treatment-induced hypomagnesemia: results from a pilot randomized trial. Vickers et al. 2021. PMID: 34938893